Novartis AG and Sanofi: SG&A Spending Patterns Compared

A Comparative Analysis of SG&A Spending: Novartis AG vs. Sanofi

In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two pharmaceutical giants, Novartis AG and Sanofi, from 2014 to 2023. Over this period, Novartis AG's SG&A expenses fluctuated, peaking in 2018 with a 13% increase from the previous year, before declining by 24% in 2023. In contrast, Sanofi's spending showed a steady upward trend, culminating in a 26% rise by 2023. This divergence highlights differing strategic priorities: while Novartis may be optimizing costs, Sanofi appears to be investing in growth. Such insights are invaluable for investors and industry analysts seeking to understand the financial health and strategic direction of these companies.